However, the decreased expression levels of P53 in WT and hypernephroma pediatric patients before the treatment may have occurred because of the production of mutated P53, which acts to increase cancer proliferation instead of inhibition [79,80,81]. This evidence concerns the gene TP53 and renal cell carcinoma.